PARSIPPANY, N.J., June  16, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&#34;embecta&#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company,

EMBC

embecta appoints Nimish Muzumdar as SVP and President, North America

Embecta names Nimish Muzumdar to lead North America growth strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PARSIPPANY, N.J., June  16, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&amp;#34;embecta&amp;#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Embecta appointed Nimish Muzumdar as Senior Vice President and President, North America, effective June 15, 2026, to lead US/Canada commercial growth. The company signals a broader shift beyond insulin delivery into obesity, autoimmune, diabetes, and anaphylaxis markets, backed by an inducement grant of 638,978 TVUs vesting over three years. This leadership change could accelerate NA revenue expansion and strategic portfolio diversification.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nimish Muzumdar named Senior VP and President, North America, at embecta; effective June 15, 2026.</li><li>Muzumdar previously led Sandoz generics to sustained growth post-spinoff from Novartis in 2023.</li><li>Inducement grant: 638,978 time-vested restricted stock units, vesting over 3 years.</li><li>Embecta aims to broaden from insulin into obesity, diabetes, autoimmune diseases, and anaphylaxis markets.</li><li>The move signals a strategic NA growth push as embecta transforms into a broader medical-supplies company.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>embecta (EMBC)</strong>: Leadership appointment may drive NA growth and broader product adoption.</li><li><strong>Novartis AG (NVS)</strong>: Sandoz spinoff context; historical tie to embecta leadership lineage.</li><li><strong>Dr. Reddy&#039;s Laboratories (RDY)</strong>: Background connection in generic pharma; contextual relevance to generic markets.</li><li><strong>Sun Pharmaceutical Industries (SUN)</strong>: Background in generics; competitive landscape context for embecta&#039;s strategic shift.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The piece centers on a leadership appointment and related equity inducement, signaling a strategic pivot and potential near-term execution gains for embecta.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>NA leadership appointment could accelerate US/Canada market share gains.</li><li>Inducement grant suggests strong retention incentives aligned with multi-year growth.</li><li>Strategic shift to broader chronic-care portfolio may affect margins and growth trajectory.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Nimish Muzumdar named Senior Vice President and President, North America, effective June 15, 2026.</li><li>Inducement grant: 638,978 time-vested restricted stock units (TVUs).</li><li>TVUs vest 20% after 1 year, 50% after 2 years, 30% after 3 years; subject to continued employment.</li><li>Emμβecta employs about 2,500 people globally.</li><li>Emμβecta is transitioning from insulin focus to broad-based medical supplies.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over the next 6–12 months on stronger North America execution and portfolio expansion.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>PARSIPPANY, N.J., June  16, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that <strong>Nimish Muzumdar</strong> has been named the company's Senior Vice President and President, North America, effective June 15, 2026.</p>  <p>Mr. Muzumdar will be responsible for leading the United States and Canada commercial teams and executing the region's long-term growth strategy. He will report to Dev Kurdikar, Chairman, President and CEO of embecta, and serve on the embecta Operating Team.</p>  <p>Mr. Muzumdar most recently served as Senior Vice President &amp; Head, Generics (Retail, Institutional, Hospitals &amp; Clinics) at Sandoz — a $1 billion division that he returned to sustained, profitable growth. Following its spinoff from Novartis in 2023, he helped shape the organization's commercial strategy, culture, and operational foundation for long-term success. In his decade-plus at Sandoz, he previously served as Director, Generics Oncology &amp; Injectables; Executive Director, Generics Oncology &amp; Injectables; and Executive Director, Retail Generics. Prior to Sandoz, he held marketing roles of increasing leadership responsibility for Ranbaxy USA, Watson Laboratories, and Dr. Reddy's Laboratories.</p>  <p>&#34;embecta is undergoing a transformation as we build on our 100-year legacy as a leader in insulin injection,&#34; said Kurdikar. "Nimish's wealth of experience in US retail pharmacy and hospital channels combined with his track record of driving growth in the highly competitive generic drugs industry will serve us well as we begin to broaden our portfolio to serve chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets."</p>  <p>Mr. Muzumdar holds a Bachelor of Science – Pharmacy from the University of Mumbai and an MBA from New York Institute of Technology.</p>  <p>Mr. Muzumdar received, as an inducement grant for his employment, a long-term incentive award of 638,978 time-vested restricted stock units (the "TVUs"). The TVUs are subject to the terms and conditions of the applicable award agreement (the "Award Agreement") provided to Mr. Muzumdar and will vest twenty percent (20%) on the first anniversary of the grant date, fifty percent (50%) on the second anniversary of the grant date, and thirty percent (30%) on the third anniversary of the grant date, subject to Mr. Muzumdar's continued employment on the vesting dates. Vesting of the TVUs is subject to acceleration in accordance with embecta's Executive Severance and Change in Control Plan. The inducement equity award was approved by embecta's Board of Directors as a material inducement to Mr. Muzumdar's entering into employment with embecta in accordance with Nasdaq Listing Rule 5635(c)(4).</p>  <p><strong>About embecta</strong><br></br>embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,500 employees around the globe. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=7p3CXQ7WJEb15t6kGVIvnOcv4YgblqO-6UjlUg62wFPKYRgg_KjyTPA06wLlk97cT2TWKtioHRVOYEmTVpM84h0jZYaPm1cJEuiG3qT4eg2oEpHDEpXAadNtuYwES_wJf8691_PVPbuYxa1nogTddDgI8tZnq6KBTz-iNM11rLDY9qJaPQuVE8WEgD7vugCMLsNaSj1otw2ZzQzfw56o4EBU7PhRi7QfVbJynRjG83TruKwkpYbMiB3K86QxjWErXwHEmw-ysW26UWBxEbU9F6bz7_N7n8YyNWvdW4zPaiDnskN6W9e-a6v1JBZidMOaNiJd0Oe0Z5Xcz-giBB4h83w20wBC42PLK54mHPNJ3zcFDQ4Oz2bmdz-WduF8qBJ7B3FNRyKgtgYf4MJTMT6fCyr7VBhfSgRw_Fvxz1wUoosEGRT1LJ3zcaWx91h6fSz3b_0RnNFNYhraKJxWc15ocwaTD4DPWBI696YpGUMw-EcFZvuu6589Sm42XNjZZ818_IFP2ZP3k4Plgl8MYSX0ucv8RUYSA1-QlnP3T58mPBSe7Z9-_dB6siQnAt7zB8dPHut6asbly-gXvto2svmuh5LsE5WF2YGyjDDe95ZYSEH-kTMB2w5YzWZ2J2tSGzSvUuIFoiatCSpyMYGp6A7w6F8fvk7uRv7JkvZm3i4tMGI3tyGtXy3y1DVt6ucxS842RcjuiRogO_noC7wiP__jAojte1lpVvQ4qvlHXCjhQVA=" rel="nofollow" target="_blank"><u>embecta.com</u></a> or follow our social channels on <a href="https://www.globenewswire.com/Tracker?data=6L2a2Is2dADuala3-sVcHOx_w-zlk_-9Bc2hjHMOkaHRJOTTc_VH9VvqpF-MWD62BkAg-1pF-dwOi6T1uMSK2x5PbmuFMQoDu7suHx9gT5aJuxLCud1HmND0FfYedeAueQSH0qQqTHTGK4ZGLn03oCr3E0aY-mHlgwXH1vbQH8D5nmz25m8zLgYxHy-hrIInJJDq4GBo2P-wXPsBrDDqFmvQwbzk3h12fnH7bD88P7tYIFWGC9JNOVtROmkUGTYFqmjawB1DS4HgowHKcObGN5ZirYwhjDOiKlBX5BgQLglIZ0EG2BcfrYIblIsUJMN8yKDt3dPRDXUAL9Ta_L6Kl8RpI2FsNjr2wA0mx9GBuvzO86AQ44m2DCvyzHVmRzZVpAsru--S0eKvjJp1UweHfdv7DHOeg62-t6BFeejg64wMOrWiuZwPU93JE8KOIl_XGyz68EkO_TLlHJkwef_N2Fx7LEiJ_zLpAiBdXEIpOMeQn_kHY3ATOJt2ugyeuZfdQqzXMknDnol6ciAOJ9HBA8V0hy4QHwL8-Z-EQIZ9snKSjN5UnMoAULV1xobrV7mTLh42qAdxQSfbw0z7cmjWjncMEZNxgrmY-MGVd13QUXUvYVAQ_0lv2jTtvvpx5Yx1IiOnUIB8bZZrXw_y12zAO-X7ygcLxUtz9yf6PctaxLtB9vlGjqFLuvKDJIMgnKEIMCQRvSCN0O3TsGAcgH-qJiDERAjgH4K6v1GWx-l9mc90ZF3VJo9XMdEMIF-Ytc_VtNdW-hOVdbBZRq-yjrPx4Q==" rel="nofollow" target="_blank"><u>LinkedIn</u></a>, <a href="https://www.globenewswire.com/Tracker?data=NwiqmuQmnMaeFyZTwzXsE7rFMQ5-1lfVJ8YtYI6uv7BSGoK_NGDHnm35qebVmM4PcLhMc-GXzDtvSmtIsNBFZuIm_L24n8W2vHLfHXGtFsr5G2P9QepoaydN9m6NNQbatp9bU70S44qrJKGJTt8Nmv1po1RRt0E9alOYzeRKgpzyeq4GFkRCmTmD4iHk6D_qTmmjyp7n56mJQC7Uy3fVFA_hBYuMzLOpokX6I3qdu9NzbtjdIeBJFRH2aJPUXuvf1Ay3BEmypHPgMHg3F9FOidNVowHJ1hGYrO6XsrJvG8x9WRBKaBopjtQolsfUzejMnZXNgsKsK7IMdbtaiB8RQBR9roQ6Yd7iEuV7qkzZhrcN1Q0zAvlpTF570v_5cZ0Iq1_Rb0n8yw5PMFW94bKsVj46uWpigcAL6UEh1294Jnj99vNM8z1sQ1bv0h5IBXEq359ttcMn154sV6yV04g1kj_HAIrfON_orRmJYjZtSRWT32uA7tKDAjvhXww-FWIM2d0fKdeBLG5FKe0yvjXtzvn9Qs0DT7bbfmMpVD2xZmevI_i-y5UaZASNwENATQA6YAwti1Kxef9lFzNv6r8NoFrbWH1bI_fSsZtYrvFV-RGVQBNF0LU278KrQUtKiDUZ796nRdAUV84NdZdzbgP1JmJrpONaE1TD4A54BI2yB-hSMuTfoSMv2ryWo2-kugWoQXYrXEDHP42tlmNyU6kUKprI-uLEV_FVQdckthwgHm2Ze1PF_0WSiZmo5yttTcdZ" rel="nofollow" target="_blank"><u>Facebook</u></a>, and <a href="https://www.globenewswire.com/Tracker?data=YN4fy-Ntg7g_t_pS0Cgb6eDkwAhsgcxrJ2JwctMCLh54zKXqqr7TfuHrwkAmH8EYHT29lBuy7kk1p8T8aZHQUpkaOWnFTS7ZRQeyqjiehsgIQ6crxJUD9MA_nje9hf8Z6RbfAgH8fhA32rZ-qCZDUsy8UbtTKc53pxx-D_XPeA1qRQTpHKSrN-6jH2YC3ji7v1GjlnzC98olxQTL_XmNcfsJHsCuFgbmHEl84HSl64N3Oj8hD3EqO7jPzxW1wGCDsTAZqLmvTlu4qsNuz324Ipfrab-9zyPZ6Wy-w-_LKZ_SbT_ueMXV-6A36AqrY0nWDLDKK4uWP70eYEBzENZ0xXjIOsoirznpTBeZkswYa0Hg7bA-2x85o_0nYLNLTgw_QBy9UvB7t1RrqR9MH7Hnz4VxP1RZFUqlfhYKt0BAbNGXXxGQ7GmNg0330dA0U_7EdoG9S5TNQmLrE6hUMP98MtcHISnfXnVzXtOYppVq9PHaxcei3p6l34kOtSESdfvvpbCp9NfvWnphTqBVPXriDuOxygM9ptL2IBb4s75am-_2HVBnaMNdipKrm9PPJE06KwMN-n40ZMB12rMDkanFWhfFZf4gyy8c1KXWSCnICbQTmRhGd0zxfliVJU4Ea1mQOp1wPoeUEoWVThB-k6i2HT3aTixMoCxQNv5MYw1g66QiV8GUY4cQ9DymYG8NL4ulvsSU17IHWzraOo3We-n1IwLKj7eOdLK4T26VNOL5IXlZFTiCh9MyGwKbiwzT4L2l" rel="nofollow" target="_blank"><u>Instagram</u></a>.</p> <table style="border-collapse: collapse; width:99%; border-collapse:collapse ;"><tr><td style="max-width:45%; width:45%; min-width:45%;"><strong>Contacts</strong></td><td style="max-width:55%; width:55%; min-width:55%;"> </td></tr><tr><td>Media</td><td>Investors</td></tr><tr><td>Christian Glazar</td><td>Pravesh Khandelwal</td></tr><tr><td>Sr. Director, Corporate Communications</td><td>VP, Head of Investor Relations</td></tr><tr><td>908-821-6922</td><td>551-264-6547</td></tr><tr><td><a href="mailto:media.relations@embecta.com" rel="nofollow" target="_blank"><u>Contact Media Relations</u></a></td><td><a href="mailto:investor.relations@embecta.com" rel="nofollow" target="_blank"><u>Contact IR</u></a></td></tr></table> <p><br></br></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NzQwMCM3NjYyOTIyIzIyNDQ1Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MGJkMTU3ZGUtYTk0NC00ZjI0LWFmNjAtY2E3YTY1OGI4NDg2LTEyNTYxMjItMjAyNi0wNi0xNi1lbg==/tiny/Embecta-Corp-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/fa3e492e-f542-4291-a7e2-bdd2c3dff424"><img src="https://ml.globenewswire.com/media/fa3e492e-f542-4291-a7e2-bdd2c3dff424/small/embecta-logo-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a></p>

Embecta appointed Nimish Muzumdar as Senior Vice President and President, North America, effective June 15, 2026, to lead US/Canada commercial growth. The company signals a broader shift beyond insulin delivery into obesity, autoimmune, diabetes, and anaphylaxis markets, backed by an inducement grant of 638,978 TVUs vesting over three years. This leadership change could accelerate NA revenue expansion and strategic portfolio diversification.

embecta appoints Nimish Muzumdar as SVP and President, North America

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News